Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort

Abstract

The clinical diagnosis of von Willebrand disease (VWD), particularly type 1, can be complex because several genetic and environmental factors affect von Willebrand factor (VWF) plasma levels. An estimated 60% of the phenotypic variation is attributable to hereditary factors, with the ABO blood group locus being the most influential. However, recent studies provide strong evidence that nonsynonymous single nucleotide variants (SNVs) contribute to VWF and factor VIII phenotypic variability in healthy individuals. This study aims to investigate the role of common VWF SNVs on VWD phenotype by analyzing data from 219 unrelated patients included in the “Molecular and Clinical Profile of von Willebrand Disease in Spain project.” To that end, generalized linear mixed-effects regression models were fitted, and additive and epistatic analyses, and haplotype studies were performed, considering five VWD-related measures (bleeding score, VWF:Ag, VWF:RCo, factor VIII:C, and VWF:CB). According to these analyses, homozygotes: for p.Thr789Ala(C) would be expected to show 39% higher VWF:Ag levels; p.Thr1381Ala(C), 27% lower VWF:Ag levels; and p.Gln852Arg(C), 52% lower VWF:RCo levels. Homozygotes for both p.Thr789Ala(C) and p.Gln852Arg(T) were predicted to show 185% higher VWF:CB activity, and carriers of two copies of the p.Thr1381Ala(T)/p.Gln852Arg(T) haplotype would present a 100% increase in VWF:RCo activity. These results indicate a substantial effect of common VWF variation on VWD phenotype. Although additional studies are needed to determine the true magnitude of the effects of SNVs on VWF, these findings provide new evidence regarding the contribution of common variants to VWD, which should be taken into account to enhance the accuracy of the diagnosis and classification of this condition. ClinicalTrials.gov identifier: NCT02869074.

Keywords

von willebrand disease - von willebrand factor - single nucleotide variants - association study

^* Nina Borràs and Iris Garcia-Martínez contributed equally to this work.

• References

• 1 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424
• 2 Zhang Z, Lindstedt M, Blombäck M, Anvret M. Effects of the mutant von Willebrand factor gene in von Willebrand disease. Hum Genet 1995; 96 (04) 388-394
• 3 Castaman G, Eikenboom JC, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost 1999; 82 (03) 1065-1070
• 4 Wahlberg TB. A method for the evaluation of clinical information, exemplified for bleeding symptoms in non-severe von Willebrand's disease type I. Methods Inf Med 1984; 23 (03) 143-146
• 5 Gill JC, Endres-Brooks J, Bauer PJ, Marks Jr WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69 (06) 1691-1695
• 6 Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37 (01) 89-101
• 7 Smith NL, Chen MH, Dehghan A. , et al; Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121 (12) 1382-1392
• 8 Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. J Thromb Haemost 2018; 16 (12) 2375-2390
• 9 Johnsen JM, Auer PL, Morrison AC. , et al; NHLBI Exome Sequencing Project. Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project. Blood 2013; 122 (04) 590-597
• 10 Wang QY, Song J, Gibbs RA, Boerwinkle E, Dong JF, Yu FL. Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes. J Thromb Haemost 2013; 11 (02) 261-269
• 11 Auton A, Brooks LD, Durbin RM. , et al; 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 2015; 526 (7571): 68-74
• 12 Flood VH, Gill JC, Morateck PA. , et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116 (02) 280-286
• 13 Flood VH, Friedman KD, Gill JC. , et al. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood 2013; 121 (18) 3742-3744
• 14 Batlle J, Perez-Rodriguez A, Pinto JC, Fraga EL, Rodriguez-Trillo Tch A, Fernanda Lopez-Fernandez M. Diagnosis and management of von Willebrand disease in Spain. Semin Thromb Hemost 2011; 37 (05) 503-510
• 15 Batlle J, Pérez-Rodríguez A, Corrales I. , et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm. Thromb Haemost 2016; 115 (01) 40-50
• 16 Tosetto A, Rodeghiero F, Castaman G. , et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4 (04) 766-773
• 17 Borràs N, Batlle J, Pérez-Rodríguez A. , et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. Haematologica 2017; 102 (12) 2005-2014
• 18 Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood 2015; 125 (13) 2029-2037
• 19 Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet 2013; ; Chapter 7: Unit7 20
• 20 Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4 (07) 1073-1081
• 21 Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 2015; 31 (16) 2745-2747
• 22 Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138 (11) 923-936
• 23 Burnham K, Anderson D. Model Selection and Inference: A Practical Information-Theoretic Approach. 2nd Edition. Heidelberg, Germany: Springer; 2002
• 24 Johnson PC. Extension of Nakagawa & Schielzeth's R ² _GLMM to random slopes models. Methods Ecol Evol 2014; 5 (09) 944-946
• 25 Nakagawa S, Johnson PCD, Schielzeth H. The coefficient of determination R ² and intra-class correlation coefficient from generalized linear mixed-effects models revisited and expanded. J R Soc Interface 2017; 14 (134) 20170213
• 26 Lefcheck J. PiecewiseSEM: piecewise structural equation modelling in r for ecology, evolution, and systematics. Methods Ecol Evol 2016; 7 (05) 573-579
• 27 Bates D, Maechler M, Bolker B. , et al. Fitting linear mixed-effects models using lme4. J Stat Softw 2015; 67 (01) 1-48
• 28 Delignette-Muller M, Dutang C. fitdistrplus: an R package for fitting distributions. J Stat Softw 2015; 64 (04) 1-34
• 29 Dion I, Lahaye M, Salmon R, Baquey C, Monties JR, Havlik P. Blood haemolysis by ceramics. Biomaterials 1993; 14 (02) 107-110
• 30 Fallin D, Schork NJ. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet 2000; 67 (04) 947-959
• 31 Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68 (04) 978-989
• 32 Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005; 76 (03) 449-462
• 33 Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70
• 34 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300
• 35 Ahmad F, Kannan M, Biswas A, Saxena R. Impact of 789Ala/Ala genotype on quantitative type of von Willebrand disease. Ann Hematol 2009; 88 (05) 479-483
• 36 van Loon JE, Kavousi M, Leebeek FW. , et al. von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population. J Thromb Haemost 2012; 10 (07) 1262-1269
• 37 Lacquemant C, Gaucher C, Delorme C. , et al; The GENEDIAB Study Group and the DESIR Study Group. Association between high von willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. Kidney Int 2000; 57 (04) 1437-1443
• 38 Klemm T, Mehnert AK, Siegemund A. , et al. Impact of the Thr789Ala variant of the von Willebrand factor levels, on ristocetin co-factor and collagen binding capacity and its association with coronary heart disease in patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes 2005; 113 (10) 568-572
• 39 Zabaneh D, Gaunt TR, Kumari M. , et al. Genetic variants associated with Von Willebrand factor levels in healthy men and women identified using the HumanCVD BeadChip. Ann Hum Genet 2011; 75 (04) 456-467
• 40 Flood VH, Johnsen JM, Kochelek C. , et al. Common VWF sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD. Res Pract Thromb Haemost 2018; 2 (02) 390-398
• 41 Jorieux S, Fressinaud E, Goudemand J, Gaucher C, Meyer D, Mazurier C. Conformational changes in the D' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment. Blood 2000; 95 (10) 3139-3145
• 42 Rauch A, Wohner N, Christophe OD, Denis CV, Susen S, Lenting PJ. On the versatility of von Willebrand factor. Mediterr J Hematol Infect Dis 2013; 5 (01) e2013046
• 43 Mufti AH, Ogiwara K, Swystun LL. , et al; European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups. The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. Blood Adv 2018; 2 (13) 1585-1594
• 44 Haberichter SL, Allmann AM, Jozwiak MA, Montgomery RR, Gill JC. Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage. J Thromb Haemost 2009; 7 (04) 641-650
• 45 Tjernberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost 2004; 2 (02) 257-265
• 46 Fu Y, Zhu P, Bu DF. , et al. [A1381T and -1793G/C polymorphisms of vWF gene impact the plasma vWF levels in Yugur, Tibetan and Han nationalities of China]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012; 20 (05) 1200-1204
• 47 Yuan ZH, Hou YJ, Li Y. , et al. [Analysis of vWF gene A1381T polymorphism in patients with coronary heart disease]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011; 19 (03) 775-780
• 48 Yuan ZH, Zhao J, Zhang Y, Zhu P. [Impact of vWF gene A1381T polymorphism and ABO blood group on von Willebrand factor level in plasma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010; 18 (04) 967-971
• 49 Bharati KP, Prashanth UR. Von Willebrand disease: an overview. Indian J Pharm Sci 2011; 73 (01) 7-16
• 50 Tang W, Cushman M, Green D. , et al. Gene-centric approach identifies new and known loci for FVIII activity and VWF antigen levels in European Americans and African Americans. Am J Hematol 2015; 90 (06) 534-540
• 51 Davies JA, Bowen DJ. The association between the L1565 variant of von Willebrand factor and susceptibility to proteolysis by ADAMTS13. Haematologica 2007; 92 (02) 240-243